TY - JOUR
T1 - Enhanced relaxivity of GdIII-complexes with HP-DO3A-like ligands upon the activation of the intramolecular catalysis of the prototropic exchange
AU - Lattuada, Luciano
AU - Horváth, Dávid
AU - Colombo Serra, Sonia
AU - Fringuello Mingo, Alberto
AU - Minazzi, Paolo
AU - Bényei, Attila
AU - Forgács, Attila
AU - Fedeli, Franco
AU - Gianolio, Eliana
AU - Aime, Silvio
AU - Giovenzana, Giovanni B.
AU - Baranyai, Zsolt
N1 - Publisher Copyright:
© the Partner Organisations.
PY - 2021/3/21
Y1 - 2021/3/21
N2 - Gadolinium(iii) complexes have been employed for more than 30 years as contrast agents in magnetic resonance imaging (MRI). In order to further improve the diagnostic accuracy of enhanced magnetic resonance images or to provide comparable enhancement at a reduced administered dose, current research is focusing on the development of GdIII-complexes characterized by higher relaxivity. In this study we describe the synthesis and the equilibrium, kinetic, relaxation and structural properties of two new GdIII-complexes based on modified 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A) structure which, due to an intramolecular prototropic exchange, display more than two-fold higher relaxivity compared to currently available GdIII-based MRI contrast agents.
AB - Gadolinium(iii) complexes have been employed for more than 30 years as contrast agents in magnetic resonance imaging (MRI). In order to further improve the diagnostic accuracy of enhanced magnetic resonance images or to provide comparable enhancement at a reduced administered dose, current research is focusing on the development of GdIII-complexes characterized by higher relaxivity. In this study we describe the synthesis and the equilibrium, kinetic, relaxation and structural properties of two new GdIII-complexes based on modified 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A) structure which, due to an intramolecular prototropic exchange, display more than two-fold higher relaxivity compared to currently available GdIII-based MRI contrast agents.
UR - http://www.scopus.com/inward/record.url?scp=85103100952&partnerID=8YFLogxK
U2 - 10.1039/d0qi01333a
DO - 10.1039/d0qi01333a
M3 - Article
SN - 2052-1545
VL - 8
SP - 1500
EP - 1510
JO - Inorganic Chemistry Frontiers
JF - Inorganic Chemistry Frontiers
IS - 6
ER -